Evoke Pharma stock surges over 100%—here’s why

October 28, 2024 10:04 PM IST | By Invezz
 Evoke Pharma stock surges over 100%—here’s why
Image source: Invezz

Evoke Pharma Inc (NASDAQ: EVOK) opened well over 100% up on Monday after reporting positive results for a study on its metoclopramide nasal spray.  

The pharmaceutical company said its nasal spray known broadly as GIMOTI offers substantial benefits to patients of diabetic gastroparesis (DGP) on GLP-1 receptor agonists.

Evoke conducted that study in collaboration with EVERSANA and the results were reported today at the 2024 Annual Meeting of the American College of Gastroenterology (ACG).

Evoke Pharma stock has now more than tripled since the first week of September.  

Why does it matter for Evoke Pharma stock?

GIMOTI helped reduce all-cause visits to the emergency department in patients of DGP using GLP-1 receptor agonists by a whopping 91% in the aforementioned retrospective study that analysed a cohort comprising 92 patients.

Office visits and hospital outpatient visits saw a decline of 41% and 89% as well in the group on the company’s metoclopramide nasal spray.

The data that Evoke Pharma presented today is particularly significant considering a continued increase in the number diabetic patients on GLP-1 receptor agonists. Matt D’Onofrio – its chief executive said in a press release today:

This study combined with the earlier real-world data presented at key conferences, reinforces GIMOTI’s potential to improve outcomes for patients and reduce the overall financial burden on the healthcare system.

Following today’s surge on the back of GIMOTI study results, Evoke Pharma stock has returned to the price at which it started this year (2024).

Other recent developments at Evoke Pharma

The announcement arrives shortly after Evoke Pharma secured about $3.0 million via exercise of warrants.

The company expects this new capital to help with commercialisation of GIMOTI.

In August, the Nasdaq-listed firm reported its financial results for the second quarter that missed Street estimates.

Evoke lost 93 cents a share on $2.55 million in revenue.

Analysts, in comparison, were at 6 cents per share only and $2.98 million, respectively.

At the time, CEO D’Onofrio told investors:

We are continuing to see growth in all phases of our business with increases in HCPs prescribing, patients taking GIMOTI, improvements in covered prescriptions with each showing our best performance in quarter over quarter growth in Q2.

Other notable developments at EVOK in recent weeks include appointment for Benjamin Smeal as a Class II director.

Smeal has previously held positions at Kenmare Management and Willet Advisors.

Note that Evoke Pharma is not a very widely covered stock among Wall Street analysts and it doesn’t pay a dividend at writing.

The post Evoke Pharma stock surges over 100%—here’s why appeared first on Invezz


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Sponsored Articles


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.